Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo
Long-Term Follow-Up Study of Patients With Moderate to Severe, Painful Osteoarthritis of the Knee Who Participated in a Randomized, Placebo-Controlled Study of UBX0101
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Coastal Clinical Research, LLC.
-
-
Arizona
-
Tempe, Arizona, United States, 85283
- Fiel Family and Sports Medicine
-
Tucson, Arizona, United States, 85712
- Tucson Orthopaedic Institute
-
-
California
-
La Mesa, California, United States, 91942
- BioSolutions Clinical Research Center
-
Walnut Creek, California, United States, 94598
- Diablo Clinical Research
-
-
Florida
-
Miami, Florida, United States, 33143
- Well-Pharma Medical Research
-
Sunrise, Florida, United States, 33351
- Precision Clinical Research
-
The Villages, Florida, United States, 32159
- Premier Medical Associates
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Chicago Clinical Research Institute
-
-
Kansas
-
Wichita, Kansas, United States, 67207
- The Alliance for Multispecialty Research
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- Center for Pharmaceutical Research
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Hassman Research Institute
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque Clinical Trials
-
-
New York
-
Hartsdale, New York, United States, 10530
- Drug Trials America
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, Inc.
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406
- Arcis Healthcare LLC dba Lowcountry Orthopaedics and Sports Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with knee OA who have completed a randomized placebo-controlled study of UBX0101.
- Patients who are willing and able to consent to having blinded, long-term follow-up; consent via legally authorized representative is not accepted.
Exclusion Criteria:
- Patients with any condition that, in the opinion of the Investigator, would likely interfere with adhering to the study schedule of visits for 12 months.
- Patients who are scheduled to undergo knee arthroplasty on either knee during the study.
- Patients who anticipate arthroscopic surgery on either knee at any time during the study.
- Patients who plan to receive treatment with an anti-nerve growth factor agent during the study.
- Patients who plan to participate in another investigational study (including interventional studies of investigational drugs and investigational treatments [e.g., braces, stem cells, and procedures]) during the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients from a randomized placebo-controlled study of UBX0101
Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
|
This is an observational study.
No intervention is administered.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of adverse events up to 1 additional year of follow up.
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UBX0101-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.